InSignals wins €317,762 EU grant, plans Parkinson's app
What's the deal? InSignals NeurotechDealroom has a profile for this one. Try Dealroom → has won a €317,762 grant co-financed by the European UnionDealroom has a profile for this one. Try Dealroom → under the Portugal 2030Dealroom has a profile for this one. Try Dealroom → framework, via the NORTE 2030Dealroom has a profile for this one. Try Dealroom → programme. The Portuguese medtech startup, in which Frontier IPDealroom has a profile for this one. Try Dealroom → holds a 32.9% stake, will use the money to extend its proprietary Parkinson's-monitoring algorithms to run on third-party wearables such as smartwatches and smart rings.
What's the endgame? InSignals builds clinically validated technology for objective measurement of Parkinson's symptoms, including rigidity, on which it holds patents. Integrating with consumer devices would enable continuous, real-world monitoring outside clinics — supporting more responsive treatment, including deep brain stimulation and, potentially, infusion-based therapies.
Why now? The grant is a step up from the company's previous funding, a PRR Green Vouchers grant now bankrolling a separate mobile app. That app, aimed at patients and caregivers, will enable ongoing symptom monitoring and better communication with clinicians — pushing InSignals beyond clinical tools into patient-facing digital health.
Who's behind it? InSignals is a spin-out from Portugal's INESC TECDealroom has a profile for this one. Try Dealroom →, backed by São João University Hospital and the University of Porto. It commercialises research by Professor João Paulo CunhaDealroom has a profile for this one. Try Dealroom →, its co-founder and chief science officer.
"Our vision has always been to combine rigorous clinical science with accessible digital technologies that can transform the management of Parkinson's disease," Cunha said. "It's especially rewarding to see people using our technology at home."
What's next? InSignals is running a seed round to fund medical regulatory compliance and international expansion, courting investors who could benefit from Portugal's co-investment programmes. Its technology has been tested in more than 200 patients across multi-centre studies in Portugal, the Netherlands, and Spain.
The signal: The grant is modest against Frontier IPDealroom has a profile for this one. Try Dealroom →'s larger portfolio wins in 2026 — including a €25 million round for 2D Photonics — and the group's own £4 million raise. But it shows validation reaching earlier-stage, non-flagship holdings, broadening Frontier IP's story beyond graphene and photonics into medtech.
Image credit: Generated with Gemini
Read more: MarketScreener
